Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of FALCO HOLDINGS Co., Ltd.. A complete text table follows the diagram.
Clinical testing remains the core, while ICT is expanding through cloud medical systems as pharmacy economics tighten.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Clinical Testing Business | 1 | 13.4B | 62.0% of reported total |
| Dispensing Pharmacy Business | 1 | 7.5B | 34.8% of reported total |
| ICT Business | 1 | 681M | 3.1% of reported total |
| Revenues From External Customers | 2 | 21.6B | Reported six-month total · ¥21.6B |
| Operating profit | 3 | 1.1B | 5.0% operating margin |
| Operating costs & expenses | 3 | 20.6B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 1.3B | Reported pretax result |
| Falco is using clinical testing and ICT to offset pharmacy reimbursement pressure | 3 | 210M | Clinical Testing revenue grew 2.4% and profit 28.8%, ICT revenue grew 26.6% and profit 118.7%, while Dispensing Pharmacy revenue fell 2.6% and profit 30.4%. |
| Net profit attributable to owners | 5 | 803M | Reported parent-company result |
| Tax, attribution & other | 5 | 485M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Clinical Testing Business | Revenues From External Customers | 13.4B |
| Dispensing Pharmacy Business | Revenues From External Customers | 7.5B |
| ICT Business | Revenues From External Customers | 681M |
| Revenues From External Customers | Operating profit | 1.1B |
| Revenues From External Customers | Operating costs & expenses | 20.6B |
| Operating profit | Profit before tax | 1.1B |
| Falco is using clinical testing and ICT to offset pharmacy reimbursement pressure | Profit before tax | 210M |
| Profit before tax | Net profit attributable to owners | 803M |
| Profit before tax | Tax, attribution & other | 485M |